The new investment, financial terms of which were not disclosed, is intended to build on the non-exclusive partnership the firms set up in 2009 that focused on the development of endpoint’s Pulse platform.
Pulse lets users to build systems from reusable elements, such as date of birth and subject ID, and create additional factors that can be implemented and saved for future use.
This contrasts with other IRTs that require study elements to be created for each trial, according to endpoint.
James Esinhart, senior VP of global scientific affairs told Outsourcing-pharma.com the new investment will allow endpoint to expand its project support team and fund further development of the technology.
“The vision of Pulse is to put the IRT design in the hands of the people who best know and understand the clinical study requirements,” Esinhart said, adding that part of the project will be to develop it as a SaaS offering.
“We believe this investment will further enhance the satisfaction of all users, whether they are our clients or not, to hopefully solidify their desire to make use of endpoint's technology for all their future studies.”
Chiltern holds a minority stake in endpoint. However, it is not the only CRO to have teamed up with the firm which is fine by Esinhart, perhaps surprisingly given the competitive nature of the sector.
“endpoint's services are available to all and we couldn't be happier to have our industry colleagues affirming our belief that it is an innovative, cost effective, and overall great technology.
“Our goal from the start has been to support endpoint's continued growth as an industry leader in IRT. Jon (Dole) and Tom (O'Connell) and their team are the ones actually making this happen. We have no plans nor see the benefit to buying the technology outright."